Cover ImageSALE
市場調查報告書

下一代生技藥品的全球市場:2016∼2020年

Global Next-Generation Biologics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 407947
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
Back to Top
下一代生技藥品的全球市場:2016∼2020年 Global Next-Generation Biologics Market 2016-2020
出版日期: 2016年11月25日 內容資訊: 英文 124 Pages
簡介

全球下一代生技藥品市場,預計從2016年到2020年以14.42%的年複合成長率擴大。

本報告提供全球下一代生技藥品市場相關調查,市場現狀與未來發展預測,各分類市場趨勢,各地區趨勢,及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 市場情況

  • 市場概要
  • 波特的五力分析

第6章 各用途市場市場區隔

  • 再生醫療
  • 新一代抗體
  • 下一代胰島素產品
  • 下一代重組的凝血因子

第7章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區市場

第8章 推動市場的要素

  • ADC的需求擴大
  • 技術創新
  • 償付支援
  • 生技藥品的特別法律規章藥物指定

第9章 促進要素的影響

第10章 市場課題

  • 生技藥品製造的複雜度
  • 複雜的法律規章制度
  • 臨床實驗實施的招募臨床實驗對象的問題,成本高,臨床實驗的失敗率
  • 臨床實驗設計的重要的道德問題

第11章 促進要素與課題的影響

第12章 市場趨勢

第13章 供應商環境

  • 競爭模式
  • 主要消息
  • 其他值得注意的供應商

第14章 主要供應商分析

  • Biogen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi4
  • 武田藥品工業株式會社

第15章 附錄

第16章 關於Technavio

圖表

目錄
Product Code: IRTNTR10904

About Next-generation Biologics

According to the section 351 of the Public Health Service Act of the US FDA, a biological product is defined as a "virus, therapeutic serum, antitoxin, vaccine, toxin, blood, blood component or derivative, analogous product or allergenic product, applicable to the treatment, prevention, or cure of a condition or disease of human beings." Biologic therapeutics include virus, toxins, allergenic products, therapeutic serums, antitoxin, blood components or derivatives, vaccines, blood, proteins (except any chemically synthesized polypeptide), or analogous products, or arsphenamine or derivative of arsphenamine intended for the treatment, prevention, or cure of a disease or condition. The differences between the small molecules and biologics includes the molecular weight, structure, procedure of synthesis, and immunogenicity. Biologics usually have a higher molecular weight and a complex molecular structure. They are usually derived from living organisms, which is another important feature that differentiates it from small molecules. Biologics are also vulnerable to extreme temperatures and light.

Technavio's analysts forecast the global next-generation biologics market to grow at a CAGR of 14.42% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global next-generation biologics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of next-generation biologics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Next-generation Biologics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hofmann-La Roche
  • Novo Nordisk
  • Sanofi
  • Takeda Pharmaceuticals

Other Prominent Vendors

  • Aastrom Biosciences
  • AbbVie
  • AbGenomics
  • Acologix
  • ADC Therapeutics
  • Adocia
  • Agensys
  • AlloCure
  • AlloSource
  • ALMAC Group
  • Alphatec Spine
  • Ambrx
  • Amorcyte
  • Argos Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Athersys
  • Avita Medical
  • Baxter
  • Bayer HealthCare
  • Bellicum Pharmaceuticals
  • BioCardia
  • Biocon
  • Biodel
  • BIOGENOMICS
  • BioLife Solutions
  • BioRestorative Therapies
  • BioTissue Technologies
  • Bluebird Bio
  • Boehringer Ingelheim
  • BrainStorm Cell Therapeutics
  • Calimmune
  • Capricor
  • CARBOGEN AMCIS
  • Cell Medica
  • Celldex Therapeutics
  • Celyad (Cardio3 BioSciences)
  • Cesca
  • CryoLife
  • CSL Behring
  • Cynata Therapeutics
  • Daiichi Sankyo
  • Dance Biopharm
  • Dendreon
  • Diasome Pharmaceuticals
  • DiscGenics
  • Endo Pharmaceuticals
  • Esperance Pharmaceuticals
  • Exsulin
  • Fate Therapeutics
  • Fibrocell Science
  • Formation Biologics
  • Forticell Bioscience
  • Fortress Biotech
  • Gamida Cell
  • GENEREX
  • Genmab
  • Geron
  • GlaxoSmithKline
  • Harvard Apparatus Regenerative Technology
  • Healthpoint
  • Histogen
  • Histogenics
  • Humacyte
  • Immunocellular Therapeutics
  • Immunogen
  • Integra LifeSciences
  • InVivo Therapeutics
  • ISTO Technologies
  • Juno Therapeutics
  • Juventas Therapeutics
  • Kairos Therapeutics
  • Kensey Nash
  • Kiadis Pharma
  • Kinetic Concept
  • Living Cell Technologies
  • MacroGenics
  • MannKind
  • MaxCyte
  • MedImmune
  • Medtronic
  • Mersana Therapeutics
  • Mesoblast
  • MiMedx
  • Nanofiber Solutions
  • Nanotope
  • Neuralstem
  • NewLink Genetics
  • NGM Biopharmaceuticals
  • Northwest Biotherapeutics
  • Novartis
  • NovaRx
  • Ocata Therapeutics
  • Opexa Therapeutics
  • Oramed Pharmaceuticals
  • Organovo
  • Orteq
  • Orthofix
  • Osiris Therapeutics
  • Osteotech
  • OXFORD BioTherapeutics
  • Pfizer
  • PhaseBio Pharmaceuticals
  • Pluristem Therapeutics
  • Prima BioMed
  • Q Therapeutics
  • ReproCELL
  • RhinoCyte
  • RTI Surgical
  • SanBio
  • Sangamo
  • Shire Regenerative Medicine
  • STEMCELL Technologies
  • Stemcentrx
  • Stratatech
  • Synthon Biopharmaceuticals
  • TEI Biosciences
  • Tengion
  • Thermalin Diabetes
  • TiGenix
  • Tissue Genesis
  • TissueGene
  • Tolerion
  • VentriNova
  • Vericel
  • VeroScience
  • ViaCyte
  • VistaGen Therapeutics
  • vTv Therapeutics
  • Wockhardt
  • XOMA
  • Zimmer Biomet
  • Zymeworks

Market driver

  • Advanced technological innovations
  • For a full, detailed list, view our report

Market challenge

  • Complexities in manufacturing of biologics
  • For a full, detailed list, view our report

Market trend

  • Development of gene and cell therapy-based products
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Five forces analysis

PART 06: Market segmentation by application

  • Global regenerative medicine market
  • Global next-generation antibodies market
  • Global next-generation insulin products market
  • Global next-generation recombinant coagulation factors market

PART 07: Geographical segmentation

  • Next-generation biologics market in Americas
  • Next-generation biologics market in EMEA
  • Next-generation biologics market in APAC

PART 08: Market drivers

  • Increase in demand for ADCs
  • Advanced technological innovations
  • Reimbursement support for next-generation biologics
  • Special regulatory drug designations for biologics

PART 09: Impact of drivers

PART 10: Market challenges

  • Complexities in manufacturing of biologics
  • Complicated regulatory framework
  • Difficulties in patient recruitment for conducting clinical trials, high cost, and failure rate in clinical trials
  • Critical ethical challenges in clinical trial design

PART 11: Impact of drivers and challenges

PART 12: Market trends

  • Focus on regenerative medicines
  • Focus on oral insulin therapies
  • Development of gene and cell therapy-based products
  • Emergence of targeted and combination therapies

PART 13: Vendor landscape

  • Competitive scenario
  • Key news
  • Other prominent vendors

PART 14: Key vendor analysis

  • Biogen
  • F. Hoffmann-La Roche
  • Novo Nordisk
  • Sanofi4
  • Takeda Pharmaceuticals

PART 15: Appendix

  • List of abbreviations

PART 16: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global next-generation biologics market
  • Exhibit 03: Overview of next-generation biologics market 2016-2020
  • Exhibit 04: Key strategies in global next-generation biologics market
  • Exhibit 05: Global next-generation biologics market snapshot: Developed and emerging markets 2015
  • Exhibit 06: Global next-generation biologics market 2015-2020 ($ billions)
  • Exhibit 07: Opportunities faced by biologics industry today
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Global next-generation biologics market segmentation by therapies
  • Exhibit 10: Market share of next-generation biologics by application
  • Exhibit 11: Market overview of global regenerative medicine market
  • Exhibit 12: Sub-segmentation in regenerative medicine market
  • Exhibit 13: Global regenerative medicine market 2015-2020 ($ billions)
  • Exhibit 14: Funds from federal agencies for regenerative medicine research in 2014 ($ millions)
  • Exhibit 15: Cell therapy overview
  • Exhibit 16: Gene therapy products available in Europe
  • Exhibit 17: R&D in tissue scaffold
  • Exhibit 18: Opportunity analysis of global regenerative medicine market
  • Exhibit 19: Market overview of next-generation antibodies
  • Exhibit 20: Sub-segmentation in next-generation antibodies market
  • Exhibit 21: Global next-generation antibodies market 2015-2020 ($ billions)
  • Exhibit 22: Global next-generation antibodies market: Present and future scenario
  • Exhibit 23: Opportunity analysis of global next-generation antibodies market
  • Exhibit 24: Market overview of next-generation insulin products
  • Exhibit 25: Factors affecting global next-generation insulin products market
  • Exhibit 26: Global next-generation insulin products market 2015-2020 ($ millions)
  • Exhibit 27: Opportunity analysis of global next-generation insulin products market
  • Exhibit 28: Market overview of next-generation recombinant coagulation factors
  • Exhibit 29: Global next-generation recombinant coagulation factors market 2015-2020 ($ billions)
  • Exhibit 30: Opportunity analysis of global next-generation recombinant coagulation factors market
  • Exhibit 31: Impact of factors affecting the market 2015 and 2020
  • Exhibit 32: Global next-generation biologics market: Segmentation by geography (2015-2020)
  • Exhibit 33: Global next-generation biologics market segmentation by region: Market growth lifecycle analysis 2015
  • Exhibit 34: Overview of next-generation biologics market in Americas
  • Exhibit 35: Next-generation biologics market in Americas 2015-2020 ($ billions)
  • Exhibit 36: Stem cell research policies in Americas
  • Exhibit 37: Overview of next-generation biologics market in EMEA
  • Exhibit 38: Distribution of major cell therapy vendors in Europe 2011
  • Exhibit 39: Next-generation biologics market in EMEA 2015-2020 ($ billions)
  • Exhibit 40: Stem cell research policies in EMEA
  • Exhibit 41: Overview of next-generation biologics market in APAC
  • Exhibit 42: Global next-generation biologics market revenue by geography 2015-2020 ($ billions)
  • Exhibit 43: Key regenerative medicine market developments in Japan by global vendors 2015
  • Exhibit 44: Next-generation biologics market in APAC 2015-2020 ($ billions)
  • Exhibit 45: Stem cell research policies in APAC
  • Exhibit 46: ADC molecules currently under clinical trials
  • Exhibit 47: Advances in ADCs technology
  • Exhibit 48: Technologies used in next-generation biologics
  • Exhibit 49: Breakdown of CIRM funding in various stem cell research funding in 2014 ($ billions)
  • Exhibit 50: Active programs under CIRM in 2014
  • Exhibit 51: EC funding
  • Exhibit 52: Some of special regulatory designations approved by US FDA
  • Exhibit 53: Special regulatory designation approved by EU
  • Exhibit 54: Impact of drivers
  • Exhibit 55: Ethical issues that are faced by various institutes at different phases of cell therapy research
  • Exhibit 56: Impact of drivers and challenges
  • Exhibit 57: Impact of trends on global next-generation biologics market
  • Exhibit 58: Some of the regenerative medicines under development for the treatment of various musculoskeletal disorders
  • Exhibit 59: Planned clinical trials of iPS cell-based therapies
  • Exhibit 60: Regenerative medicines for IBS under development
  • Exhibit 61: Some of the mid- and late-stage pipeline products for regenerative medicine
  • Exhibit 62: Oral insulin pipeline portfolio
  • Exhibit 63: Gene therapies under development for hemophilia
  • Exhibit 64: Geographical presence of key vendors
  • Exhibit 65: Competitive scenario of global next-generation biologics market vendors 2015-2020
  • Exhibit 66: Biogen: Key highlights
  • Exhibit 67: Biogen: Strength assessment
  • Exhibit 68: Biogen: Strategy assessment
  • Exhibit 69: Biogen: Opportunity assessment
  • Exhibit 70: F. Hoffmann-La Roche: KADCYLA pipeline products
  • Exhibit 71: F. Hoffmann-La Roche: Key highlights
  • Exhibit 72: F. Hoffmann-La Roche: Strength assessment
  • Exhibit 73: F. Hoffmann-La Roche: Strategy assessment
  • Exhibit 74: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 75: Novo Nordisk: Highlights
  • Exhibit 76: Novo Nordisk: Strength assessment
  • Exhibit 77: Novo Nordisk: Strategy assessment
  • Exhibit 78: Novo Nordisk: Opportunity assessment
  • Exhibit 79: Sanofi: Highlights
  • Exhibit 80: Sanofi: Strength assessment
  • Exhibit 81: Sanofi: Strategy assessment
  • Exhibit 82: Sanofi: Opportunity assessment
  • Exhibit 83: Takeda Pharmaceuticals: Highlights
  • Exhibit 84: Takeda Pharmaceuticals: Strength assessment
  • Exhibit 85: Takeda Pharmaceuticals: Strategy assessment
  • Exhibit 86: Takeda Pharmaceuticals: Opportunity assessment
Back to Top